Zhiwen Fan

321 Zhongshan Road
Nanjing, 210008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Closer Association of Liver Stiffness Than Liver Fat Content With Imaging-Derived Neurovascular Coupling in a Metabolic Dysfunction-Associated Steatotic Liver Disease Cohort.

Closer Association of Liver Stiffness Than Liver Fat Content With Imaging-Derived Neurovascular Coupling in a Metabolic Dysfunction-Associated Steatotic Liver Disease Cohort.

Journal: Diabetes, obesity & metabolism

Published: April 21, 2026

SREBP2 links ACSS2-dependent acetyl-CoA biosynthesis to metaboloepigenetic activation of hepatic stellate cells and liver fibrosis.

SREBP2 links ACSS2-dependent acetyl-CoA biosynthesis to metaboloepigenetic activation of hepatic stellate cells and liver fibrosis.

Journal: Metabolism: clinical and experimental

Published: March 10, 2026

Nuclear Factor I-B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription.

Nuclear Factor I-B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: June 18, 2025

Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

Journal: Communications medicine

Published: March 06, 2025

Redox-sensitive epigenetic activation of SUV39H1 contributes to liver ischemia-reperfusion injury.

Redox-sensitive epigenetic activation of SUV39H1 contributes to liver ischemia-reperfusion injury.

Journal: Redox biology

Published: September 18, 2024

Iron regulatory protein 2 contributes to antimicrobial immunity by preserving lysosomal function in macrophages.

Iron regulatory protein 2 contributes to antimicrobial immunity by preserving lysosomal function in macrophages.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 24, 2024

Different minimal alcohol consumption in male and female individuals with metabolic dysfunction-associated fatty liver disease.

Different minimal alcohol consumption in male and female individuals with metabolic dysfunction-associated fatty liver disease.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: October 30, 2023

The chromatin remodeling protein BRG1 contributes to liver ischemia-reperfusion injury by regulating NOXA expression.

The chromatin remodeling protein BRG1 contributes to liver ischemia-reperfusion injury by regulating NOXA expression.

Journal: Life sciences

Published: September 24, 2023

Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study.

Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study.

Journal: EClinicalMedicine

Published: September 19, 2023

The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes.

The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes.

Journal: Hepatology international

Published: September 10, 2023

Machine Learning-Based Models for Advanced Fibrosis and Cirrhosis Diagnosis in Chronic Hepatitis B Patients With Hepatic Steatosis.

Machine Learning-Based Models for Advanced Fibrosis and Cirrhosis Diagnosis in Chronic Hepatitis B Patients With Hepatic Steatosis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: August 22, 2023

C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease.

C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease.

Journal: JHEP reports : innovation in hepatology

Published: August 09, 2023

Showing 1-12 of 62

Last Updated: 09/26/2026